South Africa (SA) has a high prevalence of human immunodeficiency virus (HIV) infection. People living with HIV are at markedly increased risk of developing Burkitt lymphoma (BL), which is characterized by the MYC translocation. There is a paucity of survival data of HIV-associated Burkitt lymphoma/leukaemia (HIV-BL) cases from SA, and the relationship between karyotype and outcomes has not been widely reported. Here we report the clinico-pathological characteristics of a cohort of cytogenetically confirmed HIV-BL cases. A retrospective, descriptive review was conducted of clinico-pathological features of HIV-BL patients newly diagnosed and treated between 2005 and 2014 at our tertiary academic institution in Cape Town. Only HIV-BL patients with cytogenetic evidence of a MYC translocation were included for analysis. A multivariable Cox proportional hazards model assessed the impact of variables on overall survival (OS). Forty-nine patients met inclusion criteria. Their median age was 37 years (IQR 30-43 years) and 57% (n = 28) were females. Their median CD4 count was 240 cells/μl (IQR 103-423 cells/μl). The majority, 61% (n = 30), had leukaemic presentation, and 20% (n = 10) had a complex karyotype on conventional karyotyping. Seventy-seven percent (n = 36) received various protocols of combination intensive chemotherapy, excluding rituximab. Their OS was 64% (95% CI 45-77%) at 6 months, and 34% (95% CI 17-51%) at 5 years. Leukaemic presentation and a complex karyotype gave a 2.7-fold (95% CI 1.0-6.7) and 2.6-fold (95% CI 1.1-6.6) increased risk of mortality respectively, which were statistical significant (p < 0.05). We report 49 newly diagnosed, cytogenetically confirmed HIV-BL patients at our institution over a 10-year period. There was a high proportion of complex karyotypes and leukaemic presentation, which both independently adversely affected survival. This may be due to differences in the pathobiology of HIV-BL that requires further study and could lead to therapeutic advances in this patient group.
association with human immunodeficiency virus (HIV) infection [1] . People living with HIV (PLWH) have a markedly increased incidence of NHL, particularly high grade B cell lymphomas such as BL, despite antiretroviral therapy (ART) [2] . Patients with HIV-associated BL (HIV-BL) typically present with advanced, bulky disease and a high tumour burden requiring intensive chemotherapy and rigorous supportive care [3] . Reported outcomes in HIV-BL vary, with 75% overall survival (OS) reported in a large systematic review from well-resourced countries for patients receiving ART with access to rituximab [4] . There is a paucity of similar data from South Africa (SA), particularly in the ART era [5] .
The characteristic cytogenetic feature of BL is translocation of the oncogenic transcription factor MYC from chromosome 8 to the immunoglobulin (Ig) heavy chain region on chromosome 14. The resulting translocation, t(8;14) (q24;q32), leads to MYC dysregulation and its constitutive overexpression. The variant translocations, t(2;8) (p12;q24) and t(8;22)(q24;q11), occur in a minority of BL patients, and juxtapose MYC with immunoglobulin light chain loci [6] . This dysregulation and overexpression of MYC plays a crucial role in lymphomagenesis, driving tumour cell proliferation. In the HIV negative (−ve) setting, BL is associated with a simple karyotype. Increasing karyotypic complexity has been reported to correspond with disease progression and relapse [7] . Considering the aggressive clinical presentation in HIV-BL, this group may have differing underlying biology including cytogenetic abnormalities.
The aim of this study is to report the clinico-pathological characteristics of a local cohort of cytogenetically confirmed HIV-BL cases and to identify clinical and laboratory parameters associated with leukaemic presentation and poorer survival.
Methods

Study design and participants
A retrospective descriptive study was conducted at Groote Schuur Hospital, a tertiary referral academic centre in Cape Town, South Africa. Newly diagnosed Burkitt lymphoma or leukaemia cases between January 2005 and December 2014 were identified for inclusion from a pathology database. Eligible study participants were aged ≥ 15 years and HIV positive (either a new or a known diagnosis of HIV). Patients diagnosed with BL without cytogenetic evidence of a MYC translocation, on either karyotyping or flourescence in situ hybridization (FISH) were excluded. The Human Research Ethics Committee at the University of Cape Town approved the study. All procedures followed were in accordance with institutional and national ethical standards and with the Helsinki Declaration of 1975, as revised in 2008 [8] . Informed consent was waived in view of the retrospective nature of the study. Confidentiality and anonymity of patient data was maintained throughout.
Data collection
Data was extracted from clinical, laboratory, and pharmacy records and included age, gender, histological findings, anatomical site of diagnosis, HIV status, CD4 cell count, lactate dehydrogenase (LDH), bone marrow (BM) involvement/leukaemia, conventional cytogenetic karyotype and FISH findings, cerebrospinal fluid (CSF) cytology, and flow cytometry, where available. Date of death and date last seen were obtained through hospital records, national laboratory systems information systems, and the Department of Home Affairs.
Histopathological diagnosis
The inclusion of BL patients was dependent on samples reported by registered pathologists in histopathology and haematology pathology. The diagnosis of BL was made according to the features stipulated by the World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues [9, 10] . Due to local resource limitations, not all BL cases had molecular confirmation. Burkitt leukaemia was defined as ≥ 20% Burkitt cells on peripheral blood or bone marrow aspirate, or > 25% involvement on the bone marrow trephine [11] .
Flow cytometry
Immunophenotyping performed between 2004 and 2009 (11 cases) used a four-colour panel of antibodies. CD45 gating and relevant isotypic controls were used to exclude nonspecific antibody binding. The following cell-surface antibodies were used: HLA-DR, CD34, CD14, CD13, CD4, CD2, CD117, CD7, CD56, CD19, CD10, CD33, kappa, and lambda light chains. Cytoplasmic antigens included myeloperoxidase, μ chain, CD3, CD22, CD79a, and terminal deoxynucleotidyl transferase (TdT). Samples were stained and processed using standardised protocols. Samples were analysed on a Becton Dickinson Facs-Calibur flow cytometer (BD-Biosciences, UK) and analysed using Cell Quest software. Between January 2010 and December 2014, 11 cases were analysed using 8-colour Euroflow panels and gating strategies [12] on a FACs Canto flow cytometer (BD) and analysed using Infinicyte software.
Conventional cytogenetic studies were performed on BM aspirate and body fluids, slides were G-banded with trypsin and Giemsa stain and interpreted using the International System for Human Cytogenetic Nomenclature (ISCN). A complex karyotype was defined as ≥ 3 aberrations (including IG-MYC) [7] . FISH was performed using the Vysis IGH/MYC/CEP8 tri-colour dual fusion and the MYC dual-colour break-apart rearrangement probes. Two hundred interphase nuclei were evaluated and a positive result was reported when the percentage of cells with abnormal signals was > 10% for the MYC break-apart probe or a single fusion positive result for the IGH/MYC/ CEP probe.
Therapy
Data regarding treatment was collected from the patient hospital folders and the hospital pharmacy. Burkitt lymphoma patients at our institution receive combination intensive chemotherapy protocols, which include high-dose methotrexate with folinic acid rescue. Patients were typically initially treated with debulking chemotherapy (cyclophosphamide, vincristine, prednisone (COP)) and thereafter received intensive chemotherapy according to well-defined protocols such as CODOX-M/ IVAC (cyclophosphamide, doxorubicin, vincristine, high-dose methotrexate/ifosfamide, high-dose cytarabine, and etoposide) [13] , Hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine) [14] , COPADM/CYVE (cyclophosphamide, vincristine, prednisone, doxorubicin, methotrexate, cytarabine, etoposide) [15] , or modified Milano protocol (cyclophosphamide, vincristine, methotrexate, etoposide, doxorubicin, cisplatinum, cytarabine) [16] . Intrathecal (IT) chemotherapy (methotrexate, cytarabine, and dexamethasone) was routinely administered as part of the treatment protocol. Patients with a simultaneous new diagnosis of HIV were commenced on appropriate ART according to local guidelines [17] , and ART was continued throughout chemotherapy for those receiving ART at the time of diagnosis. Due to local policies and resource limitations during the study period, none of these patients received treatment with rituximab.
Statistical methods
Categorical and continuous variables were summarised with frequencies and percentages or medians and inter-quartile ranges (IQR) respectively. Univariate comparisons between categorical variables were performed with the chi-squared test and by the use of Fisher's exact test where the expected frequency was < 5. Medians for non-parametric data were compared using the Wilcoxon rank-sum test. Time to event outcomes were computed using the Kaplan-Meier technique and were compared by using the two-tailed log-rank test. A multivariable Cox proportional hazards model was developed to assess the impact of variables on 5-year OS. Covariates in the Cox proportional hazards model were HIV status, age (< or ≥ 40 years), CD4 count (< 200 cells/μl versus > 200 cells/μl), leukaemic presentation, and complex karyotype. Survival time was calculated from the date of diagnosis until date of death from any cause or date last seen alive up to 1 January 2019. The statistical significance of the difference between survival distributions was determined by means of the logrank test. A two-sided p value of < 0.05 was considered statistically significant. STATA v14.2 (21) was used for all descriptive and quantitative analyses. Ann Hematol (2020) 99: -71 78 5 5 573 
Results
Clinico-pathological characteristics
One hundred and nine new BL patients over the study period were identified; 14 were excluded because they were HIV−ve, and a further 46 were excluded because they did not have confirmation of the MYC translocation. Forty-nine patients were therefore included for analysis. Table 1 presents their baseline characteristics. The majority of patients, 28/49 (57%), were female. The median CD4 count was 240 cells/ μl (IQR 103-423 cells/μl). Positive CSF involvement on cytospin slide examination was reported in 9/48 (19%) of patients tested. The median LDH was markedly elevated at 4119 U/l (IQR 1780-8370) reflecting the high proliferative rate of the disease, with the majority of patients, 30/49 (61%), having leukaemic dissemination. The primary site of histological/cytological diagnosis was BM in 20/49 (41%), head and neck in 10/49 (20%), abdomen and pelvis in 9/49 (18%), axillary nodes in 5/49 (10%), and breast in 3/49 (6%). Table 2 shows the relationship between CD4 count, LDH, complex karyotype, and leukaemic dissemination. The median CD4 count was lower in those with leukaemia; however, this did not reach statistical significance. The LDH was a significantly higher in patients with leukaemia (Wilcoxon rank-sum p < 0.002). A complex karyotype was not associated with leukaemic dissemination (Fisher's exact p = 0.40).
Flow cytometry was performed in 22/49 cases (45%) where there was an available, suitable sample such as peripheral blood, BM aspirate, or body fluid. In 21 cases, the immunophenotype was in keeping with involvement. A proportion of patients, 7/22 (32%), showed one or more atypical features on flow cytometry such as loss of surface light chain expression (4 cases), absence of the germinal centre marker CD10 (1 case), loss of the pan B cell marker CD20 (1 case), and presence of an immaturity marker CD34 (1 case). A summary of the cytogenetic and FISH findings is presented in Table 3 . Half of the study cohort, 24/49 (49%), had a sample suitable for conventional karyotyping, including BM aspirate, pleural fluid, and ascitic fluid. In the remaining cases, 25/49, FISH provided confirmation of the MYC translocation and was performed on a range of sample types (13 BM aspirates, 6 lymphoid tissue, 3 ascitic fluids, 1 pleural fluid, 1 breast fine needle aspirate sample, 1 peritoneal fluid, and 1 peripheral blood). The majority, 18/24 (75%), of cases confirmed by conventional cytogenetics were leukaemic and 12/ 26 (46%) of cases, confirmed by FISH only, were leukaemic. Overall, 10/49 (20%) of all cases had a complex karyotype detected on conventional karyotyping. Of those with complex karyotypes, seven cases had t(8;14), two cases had t (8;22) , and one case t(2;8) together with other cytogenetic abnormalities. Tables 4 and 5 describe the karyotypes in cases with MYC plus other cytogenetic abnormalities.
Survival outcomes
Information regarding treatment is known for 47/49 patients and survival data is available for 48/49 patients. The majority, 36/47 (77%), received a combination of alkylating agents, high-dose cytarabine, an anthracycline, and intravenous methotrexate with folinic acid rescue. All patients who did not receive high dose chemotherapy demised; their median survival time was 18 days (CI 5-24 days). The median survival for patients receiving HDC was 267 days (IQR 106-2308 days), at 6 months OS was 64% (95% CI 45-77%), at 12 months 42% (24-59%), and at 5 years 34% (95%CI 18-51%). Figure 1 shows a Kaplan-Meier survival curve by highdose chemotherapy (HDC).
On univariate analysis, there were no significant differences in survival according to age above or below 40 years (hazard ratio (HR) 1.6, log-rank p = 0.23), CD4 counts < 200 vs > 200 cells/μl (HR 1.3, log-rank p = 0.5) nor CNS involvement (HR 1.3, log-rank p = 0.7). On univariate analysis, leukaemic presentation was strongly predicted for mortality risk (HR 2.9, p = 0.01). Complex karyotype was also predicted for mortality but did not reach the statistical significance (HR 2.2, log-rank p = 0.07) on univariate analysis, but became statistically significant on multivariate analysis (Table 6 ). Leukaemic presentation continued to predict for an increased risk of death on multivariate analysis (Table 6 ). Importantly, leukaemic presentation was not associated with complex karyotype (p = 0.4) and both variables could be included in the multivariate analysis (interaction term HR = 2.2, p = 0.51). CNS involvement was not included in the final model due to the small number who had involvement confirmed on cytospin. Patients with a complex karyotype had a median survival of 70 days (IQR 6-155 days), and patients with leukaemia, a median survival of 106 days (IQR 33-288 days). Survival of the cohort by leukaemic presentation and complex karyotype are shown in Figs. 2 and 3 respectively.
Discussion
We report 49 cytogenetically confirmed HIV-BL patients newly diagnosed at our institution over a 10-year period. There was a high proportion of leukaemic dissemination (67%) and complex karyotypes (20%), which were independently associated with poorer survival. The complex karyotypes described suggest significant genomic instability in HIV-BL, which, as in other types of haematological malignancies, appears to confer poorer outcomes and response to therapy.
In areas with a low HIV prevalence, BL is rare in adults [20] ; however, BL is the most frequent NHL in HIV+ve patients in the Western Cape region of South Africa [19] . The relatively preserved median CD4 count of 240 cells/μl in our cohort confirms that BL is associated with modest rather than severe immunosuppression [18] . The reasons for this remain unclear, however implying that additional pathobiological factors besides immunosuppression contribute to the markedly increased incidence of BL in PLWH. A proportion of our patients, 7/22 (32%), displayed an atypical immunophenotype, most commonly loss of surface immunoglobulin light chain restriction, which has been previously reported in 2 patients with HIV-BL [21] .
One previous study from South Africa has reported a smaller cohort of 24 patients with HIV-BL, including 11/24 with Burkitt leukaemia. The incidence of leukaemia was thus lower than in our study and the MYC translocation was confirmed in only half of the cases. They received similar intensive chemotherapy regimens to ours, all excluding rituximab, and reported a 2-year OS of 38% (95% CI 22-54). We included only those patients who had cytogenetic confirmation of BL, and those who received high-dose combination chemotherapy achieved a 5-year OS of 34%. There have been no similar reports focusing on HIV-BL with leukaemic dissemination or complex karyotypes and their effect on outcomes; however, a complex karyotype in other MYC translocation positive lymphomas is recognised to be associated with more aggressive disease and worse outcomes [22] .
In well-resourced settings, rituximab in combination with intensive chemotherapy has become standard of care for BL [11] with 75% 5-year OS in adults with cytogenetically proven BL, even in those with HIV-BL. 23 Survival from wellresourced settings in Northern Europe and North America in the pre-rituximab era reported 47-73% 2-year OS with intensive combination chemotherapy; however, notably, these did not all have cytogenetic confirmation [13, 23, 24] .
South Africa has a huge HIV burden, with an HIV prevalence of 13% of the general population, equivalent to 7.52 million people. South Africa has the largest global ART program with 56% of HIV-infected adults receiving ART in 2017 [25, 26] . A number of factors likely contributed to the poor outcomes in this study including poor access to health care facilities, inconsistent ART therapy, diagnostic delays due to empiric therapy for tuberculosis [27] , and lack of access to rituximab as part of the chemotherapeutic regimen. The underlying biology of HIV-BL is postulated to be particularly aggressive, as we demonstrate by the high incidence of complex karyotypes and a high rate of leukaemic dissemination. The direct oncogenic role of HIV in BL lymphomagenesis has been described and may alter the pathobiology of BL. The mechanisms include direct activation of MYC in B cells by the HIV-1 protein p17 [28] and enhanced proximity of the MYC and IGH loci when incubating B cells from healthy donors with the HIV Tat protein [29] .
This study has a number of significant limitations. Firstly, this is a retrospective study based on a tertiary hospital laboratory database. Data on treatment was not uniformly available including the details of ART prior to BL diagnosis or radiological stage of disease; however, the majority, 31/49 (63%), had stage IV disease defined by CNS and BM involvement. Unfortunately, data regarding the exact cause of mortality and response to therapy was also not available. Flow cytometry of CSF was not performed routinely, and thus, CSF involvement was likely underestimated. Many BL cases did not have cytogenetic confirmation by conventional karyotyping nor FISH, and could not be included in this review. Consequently, this may have biased results by selecting for patients more likely to have leukaemic dissemination. There were only five HIV−ve BL cases with a confirmed MYC translocation during the study period, which was too few for meaningful comparison with the HIV+ve group, and we therefore chose to select and describe the HIV-BL cohort. Despite these limitations, the high number of HIV-BL cases and their clear cytogenetic findings are strengths of this study, which allow for meaningful conclusions.
In summary, we show that a high proportion of HIV-BL cases have complex karyotypes and leukaemic presentation, which independently adversely affected survival and may be due to a differences in pathobiology in HIV-BL. An important future direction for study is the detailed molecular characterisation, including next-generation sequencing of HIV-BL, which could lead to improved therapeutic approaches in this patient group.
